Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products.
Integra LifeSciences
Unlock to Claim this listing
Add / Modify Company
3.44
Overall Excellence Rating
Industry
Hospitals & HealthcareCategory
Health Care Products ManufacturingESG/Ethical Impact
We recognize that climate change affects the social and environmental determinants of health—clean air, safe drinking water, access to food and shelter, and protection from climate-related disasters through functioning and equitable societies. We strive to protect our colleagues and the environment through initiatives that limit waste, energy and water consumption, and greenhouse gas (GHG) emissions. We also do our part to minimize waste and conserve valuable resources. A diverse workforce, an inclusive culture and a welcoming work environment are business priorities and keys to our long-term success. Our executive leadership team and board of directors work closely to oversee corporate decision-making and ESG governance. The Nominating and Corporate Governance Committee has oversight responsibility for ESG matters, including material assessment, goal setting and tracking, and reporting. The Audit Committee oversees the quality and integrity of the Company’s data relating to climate change, and ESG information in the Company’s SEC filings. Both committees review the ESG report before its issuance. In addition, ESG topics are on the board’s agenda each quarter. In our inaugural 2021 ESG report, we outlined our intentions for the next three years. In this second report, we will update our stakeholders on our progress and describe what’s ahead. Our roadmap continues to focus on the material topics we identified in 2021, when we conducted our first ESG materiality assessment. In that assessment, we identified the environmental, social and governance priorities that could affect our operating performance, the financial condition of our business, our reputation, and our ability to create value for stake- holders. The materiality map on the right is the output of a comprehensive review with stakeholders and continues to align to the most critical ESG-related issues and opportunities driving Integra’s long-term performance. Our materiality mapping illustrates our alignment of priorities with our external stakeholders in product safety, customer well-being, and employee health and safety, all of which are paramount to Integra’s long-term success. We manage our business with the highest standards of ethics and integrity, as well as responsible decision-making.
Eligible Awards
Coming Soon
Claim Your Award Badges
Do you work with Us

Awards Received
2023
Revenues
1542000000
Website Traffic
Employee Rating
3.1
Customer Rating
4.2
Company Size
1000-5000
ESG Risk Rating
3